Pharvaris reported that deucrictibant, an oral bradykinin B2 receptor antagonist for hereditary angioedema (HAE), met primary and secondary endpoints in a Phase 3 on‑demand study and plans to file for approval in the first half of 2026. The company said the drug produced earlier onset of symptom relief and faster complete resolution compared with placebo in the pivotal dataset. The trial results position deucrictibant as a direct oral competitor to Kalvista’s Ekterly and other on‑demand and preventive options recently approved. Analysts noted the drug’s faster median time to symptom response and complete symptom resolution, metrics the company highlighted in investor communications. Pharvaris will use the Phase 3 data to support regulatory submissions and to advance its longer‑acting preventive formulation, which remains in a separate Phase 3 study with data expected next year.